Introduction. Adult Langerhans cell histiocytosis (LCH) is a rare inflammatory myeloid neoplasm whose cutaneous manifestations frequently mimic common dermatoses, resulting in delayed diagnosis. We report a case in which persistent skin lesions led to the diagnosis of BRAF V600E-mutated multi system LCH associated with...
Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica· Dermatology Reports· 0 citations
Introduction. Overweight and obesity affect 60%-78% of patients with psoriasis, impacting disease severity, treatment response (i.e., complete skin clearance), and clinical outcomes. This trial evaluated efficacy and safety of ixekizumab (IXE) with or without tirzepatide (TZP) in participants with psoriasis and overwei...
Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica· Dermatology Reports· 0 citations
Introduction. Thick cutaneous melanoma remains a high-risk malignancy despite advances in diagnosis and treatment. Although Breslow thickness is a well-established prognostic factor, outcomes among patients with thick melanoma remain heterogeneous. The aim of this study was to evaluate long-term outcomes, recurrence pa...
Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica· Dermatology Reports· 0 citations
Dercum’s disease (DD) is a rare chronic disorder characterized by painful subcutaneous lipomas, predominantly affecting overweight or obese middle-aged women. According to lesion distribution and extent, Hansson et al. classified DD into four types: generalized diffuse (I), generalized nodular (II), localized nodular (...
Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica· Dermatology Reports· 0 citations
Introduction. Trichophyton benhamiae is an emerging zoophilic dermatophyte increasingly reported as a cause of inflammatory tinea in children, including kerion celsi. Due to its variable epidemiological sources and often misleading exposure history, accurate identification of the infection source may be challenging and...
Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica· Dermatology Reports· 0 citations
This post-hoc analysis examined T2T outcomes in patients from UNCOVER-3 receiving the label dose of ixekizumab receiving the label dose of ixekizumab, finding early and maintained response was defined as achievement of T2T goals at Week12 maintained at 5 years (Week264).
Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica· Dermatology Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
